NEW YORK (GenomeWeb) – UK-based diagnostics firm Oncimmune said today that it has signed an agreement with US clinical laboratory Accu Reference for the firm to offer Oncimmune's EarlyCDT-Lung test to physicians.

The EarlyCDT-Lung test measures levels of seven autoantibodies in patient blood to aid in the early detection of lung cancer. Oncimmune markets the test both for detecting lung cancer before it can be picked up via imaging techniques like CT scans and for helping to evaluate whether nodules detected via imaging are likely malignant or benign.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.